Firefly Neuroscience partners with NeuroSigma to broaden access to Monarch eTNS pediatric ADHD therapy

• Firefly Neuroscience entered a strategic partnership with NeuroSigma to expand access to the Monarch eTNS System for pediatric ADHD.
• Monarch is the first FDA-cleared non-drug ADHD treatment, prescribed for children ages 7-12 not taking prescription ADHD medication.
• Deal routes Monarch through Firefly’s nationwide Evoke clinician network, pairing therapy access with objective EEG/ERP assessment and monitoring.
• NeuroSigma will provide clinical training, prescribing support, product fulfillment via a specialty pharmacy partner.
• NeuroSigma began U.S. sales of its second-generation Monarch device in July 2026 following a waitlist of more than 1,500.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Firefly Neuroscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250745PRIMZONEFULLFEED9833824) on September 25, 2026, and is solely responsible for the information contained therein.